Get the Stockscreener App
1.69
2.87%
-0.05
After Hours:
1.69
Annovis Bio Inc stock is traded at $1.69, with a volume of 620.10K.
It is down -2.87% in the last 24 hours and down -3.43% over the past month.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
See More
Previous Close:
$1.74
Open:
$1.7
24h Volume:
620.10K
Relative Volume:
0.58
Market Cap:
$71.90M
Revenue:
-
Net Income/Loss:
$-40.92M
P/E Ratio:
-0.9844
EPS:
-1.7167
Net Cash Flow:
$-26.53M
1W Performance:
-3.98%
1M Performance:
-3.43%
6M Performance:
-39.43%
1Y Performance:
-36.23%
1-Day Range:
$1.66
$1.74
1-Week Range:
$1.66
$1.825
52-Week Range:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.69 | 74.02M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
480.50 | 123.26B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.15 | 70.94B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.19 | 53.84B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
180.39 | 39.58B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
272.67 | 35.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo
Annovis Bio enrolls over 850 patients for its next Alzheimer's Disease trial - qz.com
Annovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12 - Minichart
Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial - TipRanks
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
Annovis Promotes Research Chief as Lead Drug Nears Key Trial - MyChesCo
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial - Yahoo Finance
The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified. - Bitget
Annovis Bio completes enrollment in phase 3 Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease - Moomoo
Annovis Bio completes enrollment in phase 3 Alzheimer’s trial - Investing.com
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
The buntanetap programAnnovis Bio bets on neurodegeneration trials - ad-hoc-news.de
Annovis Bio promotes Cheng Fang to chief scientific officer By Investing.com - Investing.com Australia
Annovis Bio promotes Cheng Fang to chief scientific officer - Investing.com
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - The Manila Times
Press Release: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - Moomoo
ANVSAnnovis Bio Inc Latest SEC Filings - Finviz
ANVS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnalyst Consensus Shift - dars.gov.et
Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Growth Benchmark - marketscreener.com
Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index - marketscreener.com
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com
ANVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Annovis Bio (ANVS) Shows Resilience With 4.24% Gain, Testing Key ResistanceBeta Neutral Pair - dars.gov.et
Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Annovis Bio Inc Actuals & Estimates (TRADEGATE:07X) - TradingView
Annovis Bio | DEFA14A: Others - Moomoo
ANVS Forecast — Price Target — Prediction for 2027 - TradingView
Annovis Bio Inc Actuals & Estimates (FWB:07X) - TradingView
07X Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Price to sales forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Enterprise value to revenue forward of Annovis Bio, Inc. – NYSE:ANVS - TradingView
Annovis Bio Q1 2026 Earnings: EPS Misses Wide Expectations as Pre-Revenue Biotech Advances PipelineLow Growth Earnings - DonanımHaber
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ANVS Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Biotech ChallengesAnnual Report - DonanımHaber
Annovis Bio Shareholders Approve Governance and Compensation Changes - The Globe and Mail
Why Annovis’ buntanetap pill is drawing fresh attention in Alzheimer’s race - AD HOC NEWS
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio shareholders approve all proposals at annual meeting - Investing.com UK
Annovis Bio shareholders approve all proposals at annual meeting By Investing.com - Investing.com India
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio (NYSE: ANVS) holders expand equity plan and set biennial say-on-pay - Stock Titan
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Annovis Bio Inc Stock (ANVS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director |
Apr 02 '26 |
Buy |
2.10 |
713,800 |
1,498,980 |
3,288,539 |
0.74%
3.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):